We speak to Laura Arjam, our partner at the Psychiatry Consortium, about her role, the Consortium, and what inspired her to work in mental health.
News & views
Researchers from the Grady Trauma Project tell us about their research into mental health care needs and attitudes towards psychedelic therapy in marginalized and underprivileged communities
Meet Lawrence and Archie, the first students to take part in our industrial placement scheme, as they talk about what they hope to achieve over the next year …
We hear from our COMPASS green team about how their plastic-free July challenge went, from their triumphs to their learnings for the future ...
Our team member and intern, Amanda, tells us about her "24 miles in 24 hours challenge" she organised to fund-raise for the crisis in Yemen.
Here are highlights of our activities in the first half of 2020 as we work towards building a world of mental wellbeing for everyone.
We speak to two of our team members about their career journey, decisions they made and advice they have for people about to do the same.
Two members of our COMPASS wellbeing team explain how we are looking after each other's wellbeing, as we continue to work virtually.
We speak to four of our newest team members about their experience of starting a job virtually.
Announcement of our successful $80m Series B investment round completion.
Our green team member, Amy Lawrence, on how planting trees in urban areas could help our mental wellbeing
To recognise World Health Day, we spoke to three lead investigators from our newest trial sites about their reasons for working in mental health and how they see the future.
Letter from our co-founders explaining how we have changed our work to keep people safe during this pandemic.
As we embark on our mentoring journey with The Girls’ Network one of our volunteers, Molly, explains what it takes to be an effective mentor...
Article discussing the granted psilocybin patent. Featuring a comment from co-founder George Goldsmith on what this means for COMPASS Pathways.
To make sure it is safe and effective in patients, psilocybin therapy needs to be approved by medical regulators, not legislators.
The cost of developing psilocybin therapy, with clinical trials in multiple countries, is significant, and involves considerable risk and resource. We think it’s an investment worth making.
Psilocybin therapy is unusual because it’s an innovative protocol that combines a medicine with psychological support.
Here we explain our full commitment to Open Science, including publishing the results from all our trials and supporting the publication of all results from independent studies that use our psilocybin.
Our therapist training programme has been designed by experts from the fields of psychology, psychiatry and psychedelic therapy research.
Here are highlights of our activities in the second half of 2019 that we hope will move us closer to our goal of improving mental health care for as many as possible.
Video courtesy of CNS Summit